Results 111 to 120 of about 27,758 (263)

Supplementary Figure S1 F-I from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

, 2019
Supplementary Figure S1. F, Confocal microscopy of SHEP Tet21N cells using anti-PA2G4 (red) and anti-MYCN (green) antibodies. G, Immunoblot analysis of cytoplasmic and nuclear fractions from BE(2)-C and Kelly human neuroblastoma cell lines with ...
Belamy B. Cheung (7033121), Michelle Haber (14933688), Brendan W. Stevenson (14945191), Glenn M. Marshall (9902807), Jessica Koach (322264), Bryce Keenan (8851166), Michael A. Gorman (14945194), Janith A. Seneviratne (12588178), Andre Oberthuer (5649652), Joshua A. McCarroll (12502138), Bing Liu (70818), Shizhen Zhu (51843), Jessica L. Bell (14945197), Jamie I. Fletcher (14942868), Matthias Fischer (76016), Murray D. Norris (14936951), Giovanni Perini (133035), Olivia C. Ciampa (14945182), Tao Liu (10785), Giorgio Milazzo (5090288), Stefan Hüttelmaier (76632), Daniel R. Carter (7033118), W. Clay Gustafson (14945200), Jessica K. Holien (14241329), Michael W. Parker (14945203), Taylor Lim (9989364), Jayne E. Murray (14945188), Chelsea Mayoh (14933682), Mika Herath (14945185), Hassina Massudi (313890), Andrew J. Gifford (3615305), Larissa Doughty (391900), Xiaoling Zhang (420384)   +32 more
core   +1 more source

MYCN inhibits TrkC-mediated differentiation in neuroblastoma cells via disruption of the PKA signalling pathway

Cell Death Discovery
Neuroblastoma is a rare childhood cancer in which high-risk disease, frequently driven by MYCN amplification, has poor survival. Trk-receptor expression correlates with prognosis: TrkA is observed in low-risk cases while TrkB is often expressed in high ...
Stephanie Maher, Andrew Roe, Kieran Wynne, Vadim Zhernovkov, Melinda Halasz   +4 more
doaj   +1 more source

Clinical prognostic risk model optimization based on vascular density in neuroblastoma

Pediatric Investigation, EarlyView.
This study integrates lymphatic vessel density with the International Neuroblastoma Risk Group (INRG) risk classification to develop a more accurate clinical prognostic model for neuroblastoma, demonstrating superior discrimination, calibration, and clinical net benefit compared with the INRG risk classification alone.
Qiaoyin Liu, Jialin Cui, Dong Ren, Lei Yang, Xinyu Wang, Jiatong Xu, Yifan Liu, Cong Zhang, Haoyu Xu, Lejian He, Huanmin Wang, Haiyan Cheng, Guoshuang Feng, Xin Ni, Shengcai Wang, Yaqiong Jin   +15 more
wiley   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

A novel MYCN-specific antigene oligonucleotide deregulates mitochondria and inhibits tumor growth in MYCN-amplified neuroblastoma [PDF]

, 2019
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation.
Scardovi A. L., Tonelli R., Fischer M., Montemurro L., Hrelia P., Angelucci S., Cerisoli L., Raieli S., Bartolucci D., Teti G., Amadesi C., Pession A., Venturelli L., Nieddu G., Falconi M., Lampis S.   +15 more
core   +1 more source

Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.

PLoS ONE, 2014
Neuroblastoma (NB) is the most common malignant disease of infancy. MYCN amplification is a prognostic factor for NB and is a sign of highly malignant disease and poor patient prognosis. In this study, we aimed to investigate novel MYCN-related genes and
Pei-Yi Wu, Yung-Feng Liao, Hsueh-Fen Juan, Hsuan-Cheng Huang, Bo-Jeng Wang, Yen-Lin Lu, I-Shing Yu, Yu-Yin Shih, Yung-Ming Jeng, Wen-Ming Hsu, Hsinyu Lee   +10 more
doaj   +1 more source

Letting the breaks off MYCN

, 2016
Much of our understanding of the biology of MYCN amplification in neuroblastoma is based on the exploration of transcriptional activity of MYCN.
MILAZZO, GIORGIO, Narayan, Nisha, PERINI, GIOVANNI, Paul G Ekert, Ekert, Paul G., Giorgio Milazzo, Nisha Narayan, Giovanni Perini   +7 more
core   +1 more source

Dangerous liaisons: MYCN meets condensins [PDF]

Cell Cycle, 2014
(2014). Dangerous liaisons: MYCN meets condensins. Cell Cycle: Vol. 13, No. 8, pp. 1225-1226.
Y. J. Achar, M. Foiani
openaire   +3 more sources

MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2

Journal of Experimental & Clinical Cancer Research, 2019
Background The MYCN amplification is a defining hallmark of high-risk neuroblastoma. Due to irregular oncogenes orchestration, tumor cells exhibit distinct fatty acid metabolic features from non-tumor cells. However, the function of MYCN in neuroblastoma
Yi Ding, Jie Yang, Yawen Ma, Tengteng Yao, Xingyu Chen, Shengfang Ge, Lihua Wang, Xianqun Fan   +7 more
doaj   +1 more source

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

PLoS Genetics, 2014
The rearrangement of pre-existing genes has long been thought of as the major mode of new gene generation. Recently, de novo gene birth from non-genic DNA was found to be an alternative mechanism to generate novel protein-coding genes.
Yusuke Suenaga, S M Rafiqul Islam, Jennifer Alagu, Yoshiki Kaneko, Mamoru Kato, Yukichi Tanaka, Hidetada Kawana, Shamim Hossain, Daisuke Matsumoto, Mami Yamamoto, Wataru Shoji, Makiko Itami, Tatsuhiro Shibata, Yohko Nakamura, Miki Ohira, Seiki Haraguchi, Atsushi Takatori, Akira Nakagawara   +17 more
doaj   +1 more source